Keywords: Teva, CureTech, Equity stake, R&D investment, Lymphoma, CT-011
Teva ups stake in CureTech to 75% following positive clinical results in lymphoma
Article | 14 September 2011
Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an additional $19 million investment in privately-held ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
